[go: up one dir, main page]

FR21C1039I2 - Composés destinés à traiter l'amyotrophie spinale - Google Patents

Composés destinés à traiter l'amyotrophie spinale

Info

Publication number
FR21C1039I2
FR21C1039I2 FR21C1039C FR21C1039C FR21C1039I2 FR 21C1039 I2 FR21C1039 I2 FR 21C1039I2 FR 21C1039 C FR21C1039 C FR 21C1039C FR 21C1039 C FR21C1039 C FR 21C1039C FR 21C1039 I2 FR21C1039 I2 FR 21C1039I2
Authority
FR
France
Prior art keywords
tuskive
atrophy
spinal
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1039C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
PTC Therapeutics Inc
Original Assignee
F Hoffmann La Roche AG
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1039(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, PTC Therapeutics Inc filed Critical F Hoffmann La Roche AG
Publication of FR21C1039I1 publication Critical patent/FR21C1039I1/fr
Application granted granted Critical
Publication of FR21C1039I2 publication Critical patent/FR21C1039I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR21C1039C 2014-05-15 2021-09-09 Composés destinés à traiter l'amyotrophie spinale Active FR21C1039I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
PCT/EP2015/060343 WO2015173181A1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
FR21C1039I1 FR21C1039I1 (es) 2021-10-15
FR21C1039I2 true FR21C1039I2 (fr) 2022-09-02

Family

ID=53175048

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1039C Active FR21C1039I2 (fr) 2014-05-15 2021-09-09 Composés destinés à traiter l'amyotrophie spinale

Country Status (36)

Country Link
US (1) US9969754B2 (es)
EP (3) EP4241772A3 (es)
JP (1) JP6236173B2 (es)
KR (2) KR102213740B1 (es)
CN (1) CN106459092B (es)
AR (2) AR100442A1 (es)
AU (1) AU2015261046C1 (es)
BR (1) BR112016026205B1 (es)
CA (1) CA2948561C (es)
CL (1) CL2016002836A1 (es)
CR (1) CR20160518A (es)
DK (1) DK3143025T3 (es)
EA (2) EA202090486A3 (es)
ES (2) ES2761423T3 (es)
FR (1) FR21C1039I2 (es)
HR (2) HRP20230637T1 (es)
HU (2) HUE046491T2 (es)
IL (2) IL248653B (es)
LT (1) LTC3143025I2 (es)
MA (2) MA51988A (es)
MX (1) MX371050B (es)
MY (1) MY174284A (es)
NL (1) NL301128I2 (es)
NO (2) NO2021035I1 (es)
NZ (1) NZ725008A (es)
PE (1) PE20170128A1 (es)
PH (1) PH12016502081B1 (es)
PL (2) PL3663296T3 (es)
PT (1) PT3143025T (es)
RS (1) RS59718B1 (es)
SG (1) SG11201609497TA (es)
SI (2) SI3143025T1 (es)
TW (1) TWI667239B (es)
UA (1) UA119670C2 (es)
WO (1) WO2015173181A1 (es)
ZA (1) ZA201607026B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119528903A (zh) 2012-02-10 2025-02-28 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
JP6749343B2 (ja) 2015-05-20 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための化合物
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CN108289959B (zh) 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的组合物
KR20180081520A (ko) * 2015-11-12 2018-07-16 에프. 호프만-라 로슈 아게 근위축성 측삭 경화증의 치료를 위한 화합물
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
US11702646B2 (en) 2016-11-28 2023-07-18 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを改変する方法
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
MX2020002711A (es) * 2017-09-22 2020-07-20 Hoffmann La Roche Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
KR102761837B1 (ko) * 2017-10-03 2025-02-05 에프. 호프만-라 로슈 아게 척수성 근위축증의 새로운 치료법
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
SG11202013088YA (en) 2018-06-27 2021-02-25 Reborna Biosciences Inc Prophylactic or therapeutic agent for spinal muscular atrophy
BR112020026545A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
KR102705600B1 (ko) 2018-10-19 2024-09-12 에프. 호프만-라 로슈 아게 피리도[1,2-a]피리미딘-4-온 유도체의 형태, 그의 제형 및 그의 제조 방법
CN113966219A (zh) 2019-06-12 2022-01-21 豪夫迈·罗氏有限公司 Sma的新治疗方法
US12492214B2 (en) 2019-07-31 2025-12-09 Assia Chemical Industries Ltd. Solid state forms of Risdiplam and process for preparation thereof
BR112022020418A2 (pt) * 2020-04-08 2023-05-02 Remix Therapeutics Inc Compostos e métodos para modulação de splicing
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
EP4308577B1 (en) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
KR20230157367A (ko) 2021-03-17 2023-11-16 에프. 호프만-라 로슈 아게 신규 티아졸로피리미디논 유도체
AU2022237836B2 (en) * 2021-03-18 2024-07-04 F. Hoffmann-La Roche Ag Process for preparing risdiplam
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
WO2023202501A1 (zh) * 2022-04-18 2023-10-26 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
IL319859A (en) 2022-10-14 2025-05-01 Genentech Inc Methods for treating spinal muscular atrophy
CN120530115A (zh) * 2023-01-21 2025-08-22 哈曼菲诺化学有限公司 利司扑兰的制备方法、新型中间体及其制备方法
WO2024218207A1 (en) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Thieno[3,2-b]pyridine derivatives
AU2024286618A1 (en) 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
TW202525295A (zh) 2023-10-27 2025-07-01 瑞士商赫孚孟拉羅股份公司 治療脊髓性肌肉萎縮症之新穎組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14099A3 (en) * 1996-08-06 2000-05-16 Pfizer Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
WO2009042907A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
US8932818B2 (en) * 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
WO2010019326A1 (en) 2008-08-14 2010-02-18 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
USRE47689E1 (en) * 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
PL2809322T3 (pl) * 2012-01-26 2019-11-29 Ptc Therapeutics Inc Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
CN119528903A (zh) 2012-02-10 2025-02-28 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
CN108289959B (zh) 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的组合物

Also Published As

Publication number Publication date
PL3143025T3 (pl) 2020-03-31
FR21C1039I1 (es) 2021-10-15
IL248653A0 (en) 2017-01-31
BR112016026205A8 (pt) 2021-07-20
AU2015261046C1 (en) 2019-07-25
SG11201609497TA (en) 2016-12-29
KR102213740B1 (ko) 2021-02-09
IL270027B (en) 2020-08-31
CN106459092B (zh) 2019-10-15
HRP20230637T1 (hr) 2023-09-29
JP6236173B2 (ja) 2017-11-22
EP3143025A1 (en) 2017-03-22
HRP20192159T1 (hr) 2020-02-21
ZA201607026B (en) 2022-05-25
ES2761423T3 (es) 2020-05-19
JP2017515863A (ja) 2017-06-15
MA39995B1 (fr) 2019-11-29
AR100442A1 (es) 2016-10-05
EP4241772A2 (en) 2023-09-13
PT3143025T (pt) 2019-12-03
EA202090486A3 (ru) 2020-08-31
WO2015173181A1 (en) 2015-11-19
ES2949660T3 (es) 2023-10-02
NO2025038I1 (no) 2025-08-14
MX2016014547A (es) 2017-02-23
US9969754B2 (en) 2018-05-15
KR20170003687A (ko) 2017-01-09
SI3663296T1 (sl) 2023-08-31
NL301128I2 (nl) 2021-10-25
US20170197990A1 (en) 2017-07-13
RS59718B1 (sr) 2020-01-31
MX371050B (es) 2020-01-14
AR131260A2 (es) 2025-03-05
CA2948561A1 (en) 2015-11-19
NO2021035I1 (no) 2021-09-10
EP3663296B1 (en) 2023-05-17
PH12016502081B1 (en) 2022-11-23
AU2015261046B2 (en) 2019-04-18
MA51988A (fr) 2021-01-20
EA201692280A1 (ru) 2018-07-31
PH12016502081A1 (en) 2017-01-09
CR20160518A (es) 2017-02-21
CA2948561C (en) 2019-10-22
KR20210014219A (ko) 2021-02-08
MY174284A (en) 2020-04-01
UA119670C2 (uk) 2019-07-25
CL2016002836A1 (es) 2017-04-21
KR102256013B1 (ko) 2021-05-26
SI3143025T1 (sl) 2020-01-31
BR112016026205A2 (pt) 2017-08-15
IL248653B (en) 2019-11-28
CN106459092A (zh) 2017-02-22
EA035068B1 (ru) 2020-04-23
TW201609738A (zh) 2016-03-16
EP3663296A1 (en) 2020-06-10
EP3143025B1 (en) 2019-10-09
DK3143025T3 (da) 2019-12-09
PL3663296T3 (pl) 2023-08-07
NL301128I1 (es) 2021-09-22
HUS2100037I1 (hu) 2021-10-28
EA202090486A2 (ru) 2020-06-30
PE20170128A1 (es) 2017-03-16
EP4241772A3 (en) 2023-11-15
TWI667239B (zh) 2019-08-01
NZ725008A (en) 2019-11-29
LTC3143025I2 (es) 2023-11-10
HUE046491T2 (hu) 2020-03-30
LTPA2021010I1 (es) 2021-10-11
AU2015261046A1 (en) 2016-10-27
BR112016026205B1 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
FR21C1039I2 (fr) Composés destinés à traiter l'amyotrophie spinale
IL271046A (en) Compounds for treating huntington's disease
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL258402A (en) Electroporation for obesity or diabetes treatment
ZA201608108B (en) Huntington's disease therapeutic compounds
DK3386511T3 (da) Fremgangsmåder til behandling af huntingtons sygdom
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
EP3445750A4 (en) THERAPEUTIC COMPOUNDS
JP1671730S (ja) 医療用加湿器用タブ用部品
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
EP3347334A4 (en) DEHYDROHALOGENICATION OF FLUOROCHOLE HYDROGEN
MA41169A (fr) Composés antibactériens à large spectre d'activité
LT3113778T (lt) Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui
IL259297A (en) Heterocyclic compounds for the treatment of disease
DK3724173T3 (da) Forbindelser til behandling af neuromuskulære lidelser
HUE042043T2 (hu) Malária megelõzésére vagy kezelésére alkalmas triaminopiridin-vegyületek
PL3463328T3 (pl) Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi
EP3259254A4 (en) THERAPEUTIC COMPOUNDS
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme
LT3119386T (lt) Kompozicija, skirta panaudoti su tarpslanksteliniais diskais susijusio skausmo gydymui